戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e "classic' treatment therapy (Pyrimethamine/Sulfadiazine).
2 ethod for separation and preconcentration of sulfadiazine.
3 h those coated with chlorhexidine and silver sulfadiazine.
4 atheter coated with chlorhexidine and silver sulfadiazine.
5  to use the combination of pyrimethamine and sulfadiazine.
6 rs impregnated with chlorhexidine and silver sulfadiazine.
7 as impregnated with chlorhexidine and silver sulfadiazine.
8  in vitro resistance to chlorhexidine-silver sulfadiazine.
9 ated with chlorhexidine gluconate and silver sulfadiazine.
10 nology and used as a novel device to extract sulfadiazine.
11 .4-1196.7 mug kg(-1) in chicken samples) and sulfadiazine (109.8 mug kg(-1) in a beef sample) exceedi
12 rs impregnated with chlorhexidine and silver sulfadiazine (28 of 356 catheters [7.9 percent] vs. 87 o
13 niline (DMABN), sotalol (a beta-blocker) and sulfadiazine (a sulfonamide antibiotic) exhibited a mark
14            Catheters impregnated with silver sulfadiazine and chlorhexidine had a smaller proportion
15 iple-lumen catheters impregnated with silver sulfadiazine and chlorhexidine.
16 se of medium containing inhibitors of silver sulfadiazine and chlorhexidine.
17 ration and catheters impregnated with silver sulfadiazine and chlorhexidine; b) to decrease the numbe
18 ve, is the combination of pyrimethamine with sulfadiazine and folinic acid.
19 in organic and non-organic vegetables, where sulfadiazine and mycophenolic acid were detected.
20 be compliant, but two were positive; one for sulfadiazine and the other for sulfamethoxipyridazine.
21 an until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in c
22 s of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infect
23 n, tobramycin, chloramphenicol, doxycycline, sulfadiazine, and trimethoprim-sulfamethoxazole [TMP-SMX
24 th a combination of chlorhexidine and silver sulfadiazine appear to be effective in reducing the inci
25 ptic combination of chlorhexidine and silver sulfadiazine are efficacious in reducing the incidence o
26  control mice were infected and treated with sulfadiazine beginning 4 days after infection for 3 week
27                     The chlorhexidine-silver sulfadiazine catheter is well tolerated, reduces the inc
28   The second-generation chlorhexidine-silver sulfadiazine catheter is well tolerated.
29 e cultured from the chlorhexidine and silver sulfadiazine central venous catheters.
30 atheter coated with chlorhexidine and silver sulfadiazine (CH/SS).
31 e impact of the antiseptic effects of silver sulfadiazine-chlorhexidine-impregnated central venous ca
32 were noninferior to chlorhexidine and silver sulfadiazine coated central venous catheters with respec
33 with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal blood and observa
34  AgNO3 and 5 times lower than that in silver sulfadiazine cream 1%.
35  plate, and about 6 times faster than silver sulfadiazine cream.
36                              At 6 days after sulfadiazine discontinuation, cerebral tachyzoite-specif
37 n the former than the latter at 5 days after sulfadiazine discontinuation.
38 e treated with control serum at 3 days after sulfadiazine discontinuation.
39 reated with control antibody at 3 days after sulfadiazine discontinuation.
40  soil system (DT(50) = 77 days), followed by sulfadiazine (DT(50) = 53 days), trimethoprim (DT(50) =
41 % (n=6) were obtained at 60mugL(-1) level of sulfadiazine for intra- and inter-day analysis respectiv
42 oup and 0.9% of the chlorhexidine and silver sulfadiazine group.
43 s were noted in the chlorhexidine and silver sulfadiazine group.
44 rs impregnated with chlorhexidine and silver sulfadiazine have recently been introduced for the preve
45 ses suggest that use of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in pat
46 omized trials comparing chlorhexidine-silver sulfadiazine-impregnated central venous catheters with n
47 term use (2-10 days) of chlorhexidine-silver sulfadiazine-impregnated multilumen central venous cathe
48 s catheters; and use of chlorhexidine-silver sulfadiazine-impregnated or minocycline-rifampin-impregn
49 method was successfully applied to determine sulfadiazine in honey, milk, human urine and environment
50 theters coated with chlorhexidine and silver sulfadiazine in preventing colonization and infection wi
51 ulfonamide antibiotics (sulfamethoxazole and sulfadiazine) in the presence of untreated or preoxidize
52 uracil (n = 480) or chlorhexidine and silver sulfadiazine (n = 480).
53 mphenicol (n = 246), doxycycline (n = 2351), sulfadiazine (n = 870), and TMP-SMX (n = 23 602).
54 ternal surfaces) or chlorhexidine and silver sulfadiazine (on only the external surface).
55 ated with chlorhexidine gluconate and silver sulfadiazine (P < .01).
56 nded treatments for TE are pyrimethamine and sulfadiazine (P-S) or pyrimethamine and clindamycin (P-C
57 se impregnated with chlorhexidine and silver sulfadiazine; P<0.002).
58 ine and rifampin or chlorhexidine and silver sulfadiazine reduces the rates of catheter colonization
59 [95% CI, .14-.82]), and chlorhexidine-silver sulfadiazine (RR, 0.60 [95% CI, .50-.72]) impregnations
60 eloped to determine two common sulfonamides; sulfadiazine (SDZ) and sulfamethoxazole (SMX).
61 amethazine (SMT), sulfamethoxazole (SMX) and sulfadiazine (SDZ) in imported Pangasius catfish product
62 d for the extraction and preconcentration of sulfadiazine (SDZ) in milk, honey and water samples prio
63 ized oxidation of the sulfonamide antibiotic sulfadiazine (SDZ) was studied.
64 ible for detection and interferences namely, sulfadiazine (SDz), sulfathiazole (STz) and sulfamerazin
65  assay reveal that 3 of these alleles encode sulfadiazine (Sdz)-sensitive enzymes.
66 methods for the electrochemical detection of Sulfadiazine (SF).
67 d with selected frequently used antibiotics (sulfadiazine, sulfamethazine, sulfamethoxazole, trimetho
68  severe TE and died after discontinuation of sulfadiazine, those that had received the cells did not
69 t (SCID) mice were infected and treated with sulfadiazine to establish a chronic infection.
70     SCID mice were infected and treated with sulfadiazine to establish a chronic infection.
71 ected, and one group received treatment with sulfadiazine to prevent tachyzoite proliferation during
72  mice and transferred them into infected and sulfadiazine-treated athymic nude mice, which lack T cel
73  severe TE and died after discontinuation of sulfadiazine treatment due to the reactivation of infect
74                            Three days later, sulfadiazine was discontinued to initiate reactivation o
75                                 The retained sulfadiazine was eluted using 180muL of methanol/acetic
76  and with chlorhexidine gluconate and silver sulfadiazine were evaluated.
77 ernally coated with chlorhexidine and silver sulfadiazine when used in critically ill patients.
78 thoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S. equi This study indicates trimethop
79  as an acceptable surrogate for trimethoprim-sulfadiazine with S. equi.
80 susceptibility test results for trimethoprim-sulfadiazine with Streptococcus equi subspecies are inte